Rheumatoid arthritis (RA) is a chronic, inflammatory, autoimmune, and multisystemic rheumatic disease that affects joints, many organs, and systems. Its prevalence increases with aging and the disease is seen in 2% of the older patients [1-3]. Late-onset RA is defined as RA that occurs in individuals over the age of 60~65 years [4]. Clinically, while early-onset RA has an insidious onset, late-onset RA appears more acute. Large joints such as the shoulder are affected in late-onset RA compared to early-onset RA [5]. In terms of clinical findings, comorbid diseases are more common in late-onset RA compared to early-onset RA [6,7]. RA has significantly worse consequences on physical functioning [8]. The disease significantly affects social relations, family life, and psychological state [8]. Patients may have difficulty in fulfilling their daily duties, may have to change occupations, or may retire early. Changes in self-perception associated with painful stimuli, reduced functional ability, labor, and social disability can also cause emotional and mental disorders.

Changes occur in biochemical parameters, pharmacokinetics/pharmacodynamics of drugs, functions of immune system cells, and increases in comorbid diseases along with aging. During aging, changes are observed in physical, biological, and social roles in people. RA in older people has a lower physical function, social functionality, and emotionality than adults [9]. Both psychological and sleep problems affect the quality of life in patients with RA. Sleep is important for preserving and renewing the energy that leads to the rejuvenation of the body and mind, and for strengthening the memory [10]. Approximately 70% of patients with RA have daytime sleepiness, difficulty falling asleep, and maintaining sleep [11]. It is thought that changes in pro-inflammatory cytokines and melatonin levels contribute to sleep disorders in RA [12].

High disease activity affects the physical and mental quality of life [13]. It has been reported that sleep quality is worse in RA patients than healthy controls and it is more difficult to achieve a satisfactory quality of life after treatment with aging [14]. Data on sleep and quality of life in older patients with RA are scarce. Our aim in this study is to evaluate sleep and quality of life in older patients with RA and to investigate the effects of disease-modifying agents on sleep and quality of life.

The study included 34 RA patients diagnosed older than 65 years and 30 healthy controls. Demographic data such as age, sex, marital status, education and employment status, smoking, lung involvenment, rheumatoid factor (RF), and anti-cyclic citrullinated peptide (anti-CCP) were recorded. Sleep quality was assessed with the Pittsburgh Sleep Quality Index and quality of life with the Short Form-36 (SF-36). There are seven components in the Pittsburgh Sleep Quality Index, each scored from 0 (no difficulty) to 3 (severe difficulty). Higher scores indicate worse sleep quality. A total Pittsburgh Sleep Quality Index score >5 was considered as poor sleep quality [15]. In SF-36, each domain’s scores range from 0 to 100, with a higher score describing a more positive state of health. Examination, laboratory values, sleep, and quality of life of the patients were evaluated before and 6 months after the diagnosis and treatment of RA patients. We excluded patients with connective tissue disease other than RA, those with a history of infection and malignancy, and patients under 65 years of age. The study protocol was approved by the Faculty of Medicine Ethics Committee of Aydin Adnan Menderes University and designed consistent with the Declaration of Helsinki (approval number: E.43227).

The mean age of the patients with a diagnosis of RA included in the study was 72.8±6.7 years, 23 of them were female and 11 of them were male. Smoking was present in 14.7% of the patients. In the control group, the mean age was 70.5±4.4 years, 9 of which were male and 21 were female. All RA patients were newly diagnosed and the duration of treatment was the same for each patient. There was no difference between RA and control groups in terms of age, gender, smoking/alcohol use, marital status, employment status, and educational status. The median total Pittsburgh Sleep Quality Index 15 in older RA patients before treatment. Total Pittsburgh Sleep Quality Index scores, physical and mental component scores were lower between the RA and control groups (p<0.001).

Sleep quality was good in 32.4% of older patients with RA before treatment. In terms of sleep quality, there was no statistically significant difference between good and poor sleep quality groups in terms of age, sex, smoking-alcohol use, marital status, employment status, education status, organ involvement, RF, anti-CCP. There were no patients using nonsteroidal anti-inflammatory drugs. Of the patients with good sleep quality in the 6th month, 76% used methotrexate, 24% leflunomide, and 60% hydroxychloroquine. There was no statistically significant difference between the two groups in terms of the use of disease-modifying antirheumatic drugs (DMARDs). Conventional synthetic DMARDs were used safely in the older patients with RA and no side effects have been observed. The mean steroid dose and Disease Activity Score-28 (DAS-28) were higher in patients with poor sleep quality than in patients with good sleep quality. The mean DAS-28 was 4.8±0.5 in patients with good sleep quality and 5.4±0.9 in patients with poor sleep quality. It was 3.3±1.4 and 4.1±1.3 after DMARD treatment, respectively. There were no significant differences in DAS-28 between sleep groups. The mean DAS-28 was 5.2 before the treatment, and it reached 3.5 after treatment (p<0.001). There were significant differences in steroid dose between groups before treatment (13.8±10.3 vs. 20.8±10.7 mg/day, p=0.008). Although the mean steroid dose was higher in patients with poor sleep quality, no significant differences were found after treatment (6.8±5.5 vs. 8.4±5.0 mg/day, p>0.05) (Table 1).

The rate of patients with poor sleep quality after treatment was found to be 26.5%. There was a statistically significant difference before and after treatment in terms of subjective sleep quality, sleep latency, sleep duration, sleep efficiency, and sleep disorder scores (p<0.01) (Figure 1). The physical function, physical role difficulty, pain, general health and social function, emotional role difficulty, mental health, and energy/vitality scores, which are physical components evaluated with SF-36 increased after treatment in RA patients. There was a statistically significant difference between before and after treatment in terms of physical function, physical role difficulty, pain, emotional role difficulty, and energy/vitality (p<0.05) (Figure 2).

A negative correlation was found between Pittsburgh Sleep Quality Index and quality of life scores before and after treatment. There was a statistically significant correlation between physical role difficulty and Pittsburgh Sleep Quality Index components such as sleep duration, sleep efficiency, sleep disturbance, and the total score. Also, a negative correlation was found between DAS-28 and physical function, physical role difficulty, pain, general health, social function, emotional role difficulty, mental health, energy/vitality before and after treatment. In addition, statistically significant correlations were found between physical function and sleep efficiency, physical role difficulty and sleep efficiency, emotional role difficulty and subjective sleep quality, energy/vitality and sleep disturbance after treatment (Table 2).

Sleep problems are generally associated with physiological and psychosocial problems in RA. The patients mainly have pain-related sleep problems. RA patients with insomnia problems have more problems in their daily lives and general health areas. Sleep problems gradually decrease the quality of life in these patients. In addition, psychological problems such as not being able to fall asleep, continuous interruption of night sleep, daytime sleepiness, anxiety, and depression affect the quality of life in these patients [16]. Subjective sleep, one of the components of the Pittsburgh Sleep Quality Index, shows the sleep quality that varies from person to person. Apart from RA, there are also sleep problems in various rheumatic diseases. High disease activity of ankylosing spondylitis is associated with poor sleep quality. A positive correlation was reported between the ankylosing spondylitis disease activity indices Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score with ESR, Ankylosing Spondylitis Disease Activity Score with CRP and sleep quality [17]. Pittsburgh Sleep Quality Index was developed in 1989 by Buysse et al. [15] and Turkish validity and reliability study was performed by Ağargün et al. [18]. A total score >5 was considered as poor sleep quality [15,18]. The cutoff value may be different depending on the language. According to the reliability and validity of the Korean version of the Pittsburgh Sleep Quality Index, the sensitivity and specificity to distinguish poor and good sleepers were 0.943 and 0.844 using the best cutoff point of 8.5 [19]. Also, The Korean version of the Pittsburgh Sleep Quality Index was used to evaluate the relationship between disease activity, depression, and quality of life for Behçet’s disease in the Korean population [20]. Sleep latency shows the time to fall asleep, sleep efficiency shows sleep quality, and daytime functionality shows how much trouble sleep causes in performing normal activities during the day [21]. A significant difference was found between the patient with RA and control groups in terms of subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, and daytime dysfunction components [22]. In another study conducted with RA patients, sleep latency, habitual sleep efficiency, sleep disturbance, and global Pittsburgh Sleep Quality Index scores were found to be statistically significantly higher in RA patients compared to the control group [23].

Sleep quality is affected by demographic characteristics, daily activities, smoking/alcohol use, environmental factors, and DMARDs. In a study investigating the effect of infliximab on sleep quality, improvement in sleep disorders was reported after infliximab infusion [24]. This was thought to be related to a decrease in tumor necrosis factor (TNF)-alpha levels in the blood rather than a decrease in joint pain. In another study, a decrease in disease activity and an increase in sleep efficiency were found with TNF-alpha blocking agents [25]. Contrary to these, there are also studies showing that RA treatment does not affect the Pittsburgh Sleep Quality Index [25,26]. In our study, the rate in the older patients group with good sleep quality was 32.4% before treatment and a Pittsburgh Sleep Quality Index score of >5, that is, poor sleep quality was 67.6%. After the treatment, the rate of patients with poor sleep quality decreased to 26.5%. In addition, a statistically significant difference was found before and after treatment in the scores of subjective sleep quality, sleep latency, sleep duration, sleep efficiency, and sleep disorder. And, in the follow-up of our older patients, no side effects associated were observed with the use of DMARDs. It has been reported that sleep disturbance and mood are associated with disease activity in RA patients [21]. And, a positive correlation was found between DAS-28 and Pittsburgh sleep quality scale scores in RA patients [23]. Also, in another study, a positive correlation was found between DAS-28 and Pittsburgh sleep quality scale score, while a negative correlation was found between the Epworth sleep scale score and DAS-28 [27]. In our study, the DAS-28 was higher in patients with poor sleep quality compared to good sleep quality both before and after treatment. There was a positive correlation between DAS-28 and Pittsburgh Sleep Quality Index both before and after treatment.

RA has significantly worse consequences on physical functioning. The disease significantly affects social relations, family life, and psychological state. Patients may have difficulty in fulfilling their daily duties, may have to change occupations, or may retire early. Painful stimuli decreased functional ability, changes in self-perception associated with labor and social inadequacy may also cause emotional and mental disorders [9]. In a study comparing the quality of life of fibromyalgia, RA, AS and healthy volunteers, the mean physical and mental component scores in all three groups were found to be lower than those of healthy volunteers [28]. The group with the lowest physical component was found to be RA, and the group with the lowest mental component was fibromyalgia. In the study, it was concluded that the disease affects the quality of life negatively in all 3 patient groups [28]. In a study evaluating sleep problems in fibromyalgia and RA, more depression, pain, and insomnia-related symptoms were reported in fibromyalgia patients than in RA patients [29]. The limitation of the study is that we could not evaluate fibromyalgia and its relationship with sleep disturbance and quality of life in our patients. In another study, all components of the SF-36 index except the physical role score were found to be lower than those of osteoarthritis [30]. In a study evaluating the quality of life with SF-36 in females aged 15~49 years, it was reported that physical role difficulties, pain, general health, vitality, emotional role difficulties, and mental health components were lower, while physical function and social functions were higher [31]. In our study, there was a negative correlation between age and quality of life components evaluated with SF-36. So, as the age increased, the scores of the quality of life components and the quality of life decreased. However, there was a significant increase in quality of life scores with treatment.

As a result, both sleep and quality of life are worse in older patients with RA before and after treatment compared to the healthy control group. In addition, aging and high disease activity are correlated with poor sleep and quality of life in RA patients. After the treatment, improvement in sleep and quality of life was observed in the patients. Again, conventional synthetic DMARDs are used safely in the older patients with RA and no side effects have been observed. Older patients with RA should be regularly evaluated in terms of sleep and quality of life, and appropriate treatment should be provided.

None.